BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 29435900)

  • 1. Increased Overall Survival and Decreased Cancer-Specific Mortality in Patients with Hepatocellular Carcinoma Treated by Transarterial Chemoembolization and Human Adenovirus Type-5 Combination Therapy: a Competing Risk Analysis.
    He C; Zhang Y; Lin X
    J Gastrointest Surg; 2018 Jun; 22(6):989-997. PubMed ID: 29435900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study.
    He CB; Lao XM; Lin XJ
    Chin J Cancer; 2017 Jul; 36(1):59. PubMed ID: 28728568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transarterial injection of recombinant human type-5 adenovirus H101 in combination with transarterial chemoembolization (TACE) improves overall and progressive-free survival in unresectable hepatocellular carcinoma (HCC).
    Lin XJ; Li QJ; Lao XM; Yang H; Li SP
    BMC Cancer; 2015 Oct; 15():707. PubMed ID: 26470869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101.
    He CB; Lin XJ
    PLoS One; 2017; 12(3):e0174769. PubMed ID: 28355305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transarterial injection of H101 in combination with chemoembolization overcomes recurrent hepatocellular carcinoma.
    He Q; Liu Y; Zou Q; Guan YS
    World J Gastroenterol; 2011 May; 17(18):2353-5. PubMed ID: 21633603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.
    Ren Y; Cao Y; Ma H; Kan X; Zhou C; Liu J; Shi Q; Feng G; Xiong B; Zheng C
    BMC Cancer; 2019 Oct; 19(1):983. PubMed ID: 31640620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Large primary hepatocellular carcinoma: transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy.
    Xu LF; Sun HL; Chen YT; Ni JY; Chen D; Luo JH; Zhou JX; Hu RM; Tan QY
    J Gastroenterol Hepatol; 2013 Mar; 28(3):456-63. PubMed ID: 23216261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis.
    Lin CW; Chen YS; Lo GH; Hsu YC; Hsu CC; Wu TC; Yeh JH; Hsiao P; Hsieh PM; Lin HY; Shu CW; Hung CM
    BMC Gastroenterol; 2020 Apr; 20(1):99. PubMed ID: 32272898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transarterial chemoembolization combined with apatinib versus transarterial chemoembolization alone for hepatocellular carcinoma with macroscopic vascular invasion: A propensity score matching analysis.
    Shen L; Chen S; Qiu Z; Qi H; Yuan H; Cao F; Xie L; Chen Q; Li W; Fan W
    J Cancer Res Ther; 2020 Sep; 16(5):1063-1068. PubMed ID: 33004748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
    Hu H; Duan Z; Long X; Hertzanu Y; Shi H; Liu S; Yang Z
    PLoS One; 2014; 9(5):e96620. PubMed ID: 24817002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Addition of Ablative Therapy Following Transarterial Chemoembolization With Survival Rates in Patients With Hepatocellular Carcinoma.
    English K; Brodin NP; Shankar V; Zhu S; Ohri N; Golowa YS; Cynamon J; Bellemare S; Kaubisch A; Kinkhabwala M; Kalnicki S; Garg MK; Guha C; Kabarriti R
    JAMA Netw Open; 2020 Nov; 3(11):e2023942. PubMed ID: 33151315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is Salvage Liver Resection Necessary for Initially Unresectable Hepatocellular Carcinoma Patients Downstaged by Transarterial Chemoembolization? Ten Years of Experience.
    Zhang Y; Huang G; Wang Y; Liang L; Peng B; Fan W; Yang J; Huang Y; Yao W; Li J
    Oncologist; 2016 Dec; 21(12):1442-1449. PubMed ID: 27486202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival benefit of transarterial chemoembolization in patients with metastatic hepatocellular carcinoma: a single center experience.
    Bettinger D; Spode R; Glaser N; Buettner N; Boettler T; Neumann-Haefelin C; Brunner TB; Gkika E; Maruschke L; Thimme R; Schultheiss M
    BMC Gastroenterol; 2017 Aug; 17(1):98. PubMed ID: 28797231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
    Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
    Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poor prognosis for hepatocellular carcinoma with transarterial chemoembolization pre-transplantation: retrospective analysis.
    Li HL; Ji WB; Zhao R; Duan WD; Chen YW; Wang XQ; Yu Q; Luo Y; Dong JH
    World J Gastroenterol; 2015 Mar; 21(12):3599-606. PubMed ID: 25834326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apatinib Combined With Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma and Portal Vein Tumor Thrombus: A Multicenter Retrospective Study.
    Fan W; Yuan G; Fan H; Li F; Wu Y; Zhao Y; Yao W; Wang Y; Xue M; Yang J; Li J
    Clin Ther; 2019 Aug; 41(8):1463-1476. PubMed ID: 31303279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic analysis of transarterial chemoembolization combined with a traditional Chinese herbal medicine formula for treatment of unresectable hepatocellular carcinoma.
    Yu Y; Lang QB; Chen Z; Li B; Yu CQ; Zhu DZ; Huang XQ; Zhai XF; Ling CQ
    Chin Med J (Engl); 2009 Sep; 122(17):1990-5. PubMed ID: 19781383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
    Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
    J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination Therapy of Radiofrequency Ablation and Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Retrospective Study.
    Tang C; Shen J; Feng W; Bao Y; Dong X; Dai Y; Zheng Y; Zhang J
    Medicine (Baltimore); 2016 May; 95(20):e3754. PubMed ID: 27196501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sunitinib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
    Chen J; Zhou C; Long Y; Yin X
    Tumour Biol; 2015 Jan; 36(1):183-91. PubMed ID: 25217986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.